Group 1 - Exelixis is actively marketing cabozantinib (Cabometyx, Cometriq) for its current indications while also developing zanzalintinib, which has seen both successes and disappointments [1] - A buy rating was assigned to Exelixis in February, indicating a positive outlook on the company's stock performance [1] Group 2 - The article reflects the author's personal opinions on biotech stocks, focusing on trading around significant events such as trial results and NDA/BLA approvals [1]